|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||May 01, 2012|
|Effective date (End):||April 30, 2015|
|Field of knowledge:||Health Sciences - Medicine - Medical Clinics|
|Principal Investigator:||Lucia da Conceição Andrade|
|Grantee:||Mauro Shigueharu Oide Junior|
|Home Institution:||Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil|
Some studies have shown that stem cell therapy has a positive effect on the recovery of renal tissue exposed to ischemia and reperfusion injury, reducing the histological damage is due to involvement of cells in the regeneration of kidney tissue. However, the mechanism of protection that promote stem cells are contradictory. Some authors report that mesenchymal stem cells used as a source of replacement cells to necrotic kidneys are not able to protect the kidney and others show that the protective effect of the cells come from other mechanism such as immune modulation. The renal dysfunction has been shown to be an important factor for systemic changes that are critical to the survival of patients, the lung, in particular, a very affected organ. The relationship between renal damage leading to lung injury may be mediated by factors such as serum cytokines and serum components of cells such as neutrophils or macrophages. We propose to evaluate whether stem cell therapy is able to protect the lungs against aggression generated by the insult of ischemia and reperfusion. To assess whether a difference in mortality among the animals who receive stem cells or placebo after ischemia and reperfusion. Experiments will be conducted in four different groups of animals: - normal controls; - group of animals treated with hematopoietic stem cells (500 ul) taken from human umbilical cord; - group of animals subjected to ischemia model (45 minutes) and reperfusion treated with placebo saline (500 ul) and the last group of animals subjected to ischemia model (45 minutes) and reperfusion and treated with hematopoietic stem cells (500 ul) taken from human umbilical cord. Hematopoietic cells or saline are administered 24 hours after ischemia and reperfusion and studies of inulin clearance, western blot, pulmonary edema, kidney and lung immunohistochemistry be performed 48 hours after ischemia and reperfusion.